These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12228010)

  • 1. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes.
    Epstein JE; Gorak EJ; Charoenvit Y; Wang R; Freydberg N; Osinowo O; Richie TL; Stoltz EL; Trespalacios F; Nerges J; Ng J; Fallarme-Majam V; Abot E; Goh L; Parker S; Kumar S; Hedstrom RC; Norman J; Stout R; Hoffman SL
    Hum Gene Ther; 2002 Sep; 13(13):1551-60. PubMed ID: 12228010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device.
    Aguiar JC; Hedstrom RC; Rogers WO; Charoenvit Y; Sacci JB; Lanar DE; Majam VF; Stout RR; Hoffman SL
    Vaccine; 2001 Oct; 20(1-2):275-80. PubMed ID: 11567774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration.
    Gramzinski RA; Millan CL; Obaldia N; Hoffman SL; Davis HL
    Mol Med; 1998 Feb; 4(2):109-18. PubMed ID: 9508788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
    Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
    Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.
    Le TP; Coonan KM; Hedstrom RC; Charoenvit Y; Sedegah M; Epstein JE; Kumar S; Wang R; Doolan DL; Maguire JD; Parker SE; Hobart P; Norman J; Hoffman SL
    Vaccine; 2000 Mar; 18(18):1893-901. PubMed ID: 10699338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
    Epstein JE; Charoenvit Y; Kester KE; Wang R; Newcomer R; Fitzpatrick S; Richie TL; Tornieporth N; Heppner DG; Ockenhouse C; Majam V; Holland C; Abot E; Ganeshan H; Berzins M; Jones T; Freydberg CN; Ng J; Norman J; Carucci DJ; Cohen J; Hoffman SL
    Vaccine; 2004 Apr; 22(13-14):1592-603. PubMed ID: 15068840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits.
    Parker SE; Borellini F; Wenk ML; Hobart P; Hoffman SL; Hedstrom R; Le T; Norman JA
    Hum Gene Ther; 1999 Mar; 10(5):741-58. PubMed ID: 10210142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
    Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
    Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers.
    Henderson EA; Louie TJ; Ramotar K; Ledgerwood D; Hope KM; Kennedy A
    Infect Control Hosp Epidemiol; 2000 Apr; 21(4):264-9. PubMed ID: 10782589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device.
    Cui Z; Baizer L; Mumper RJ
    J Biotechnol; 2003 Apr; 102(2):105-15. PubMed ID: 12697387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
    Diehl MC; Lee JC; Daniels SE; Tebas P; Khan AS; Giffear M; Sardesai NY; Bagarazzi ML
    Hum Vaccin Immunother; 2013 Oct; 9(10):2246-52. PubMed ID: 24051434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
    Hartikka J; Bozoukova V; Morrow J; Rusalov D; Shlapobersky M; Wei Q; Boutsaboualoy S; Ye M; Wloch MK; Doukas J; Sullivan S; Rolland A; Smith LR
    Hum Vaccin Immunother; 2012 Nov; 8(11):1595-606. PubMed ID: 22922766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses.
    Jiang J; Ramos SJ; Bangalore P; Fisher P; Germar K; Lee BK; Williamson D; Kemme A; Schade E; McCoy J; Muthumani K; Weiner DB; Humeau LM; Broderick KE
    Vaccine; 2019 Jun; 37(29):3832-3839. PubMed ID: 31174938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
    Launay O; Lewis DJM; Anemona A; Loulergue P; Leahy J; Sciré AS; Maugard A; Marchetti E; Zancan S; Huo Z; Rondini S; Marhaba R; Finco O; Martin LB; Auerbach J; Cohen D; Saul A; Gerke C; Podda A
    EBioMedicine; 2017 Aug; 22():164-172. PubMed ID: 28735965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Response of Inactivated Rabies Vaccine Inoculated via Intraperitoneal, Intramuscular, Subcutaneous and Needle-Free Injection Technology-Based Intradermal Routes in Mice.
    Zhao H; Li P; Bian L; Zhang W; Jiang C; Chen Y; Kong W; Zhang Y
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.